Discussing how next-gen multiomics is enabling drug development transformation in the post-COVID era.
Discussing how next-gen multiomics is enabling drug development transformation in the post-COVID era.
How Sapient’s /Deep/ Discovery can be used to identify & target TAAs that are differentially expressed on tumors.
How biomarkers discovered via nontargeted approaches can elucidate unknown disease biology to guide therapeutic development.
Now available on demand! See how high throughput discovery proteomics achieves high analytical specificity at scale.
High confidence protein IDs. Measure of PTMs. See how our method is optimized for revealing biological insights.
Examples of how multi-omics research has “moved the needle” in expanding our understanding of complex diseases.
Discussing questions such as, what can your zip code tell us about your health that your genetic code cannot?
These services enable measure of thousands of proteins in blood and tissue across diverse biological pathways.
How discovery mass spectrometry can be used to identify biomarkers to analyze, monitor & optimize bioprocessing workflows.
Dr. Nguyen joins Bruker’s Kate Stumpo for a wide-ranging conversation on her experiences in the field of omics.
